| Recruiting | A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) NCT07209111 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their S NCT06782451 | Centre Antoine Lacassagne | N/A |
| Recruiting | Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multi NCT06606366 | Centre Antoine Lacassagne | N/A |
| Recruiting | Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective NCT06575127 | Al-Azhar University | Phase 2 |
| Completed | A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors NCT06238687 | Tasly Pharmaceutical Group Co., Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gli NCT05850377 | Sociedad de Lucha Contra el Cáncer del Ecuador | — |
| Terminated | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NCT05714553 | NuCana plc | Phase 1 / Phase 2 |
| Unknown | Phase 1 First-in-human Study of JS014 NCT05296772 | Anwita Biosciences | Phase 1 |
| Active Not Recruiting | A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer NCT04987359 | Pennington Biomedical Research Center | N/A |
| Active Not Recruiting | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) NCT04976634 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Soli NCT05013554 | Sanofi | Phase 1 |
| Active Not Recruiting | EMPOWER 3: Improving Palliative Care Health Literacy and Utilization NCT04733469 | Tulane University | N/A |
| Terminated | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) NCT04726332 | Exelixis | Phase 1 |
| Active Not Recruiting | "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+. NCT05818865 | National Cancer Institute, Naples | N/A |
| Unknown | Evaluation of a Music and Interaction Intervention on Patient Distress During Whole Body Magnetic Resonance NCT06332001 | European Institute of Oncology | — |
| Active Not Recruiting | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL NCT04401020 | Sanofi | Phase 1 |
| Recruiting | AIMS Cancer Outcomes Study NCT04495790 | Advanced Integrative Medical Science Institute | — |
| Unknown | Longitudinal Analysis of Mental Disorders, Psychosocial Distress and Care Needs of Patients and Their Relative NCT04620564 | University of Leipzig | — |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963 | Ikena Oncology | Phase 1 |
| Recruiting | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | A Study of PSB205 in Subjects With Advanced Solid Tumors NCT03986606 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Phase 1 |
| Active Not Recruiting | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors NCT03845166 | Exelixis | Phase 1 |
| Recruiting | Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients NCT03873064 | University of Rome Tor Vergata | — |
| Unknown | Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors NCT03491631 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. NCT03667716 | Compugen Ltd | Phase 1 |
| Completed | Shorter Scalp Cooling Time in Paclitaxel NCT03266185 | Leiden University Medical Center | N/A |
| Completed | Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors NCT03324113 | Sanofi | Phase 1 |
| Completed | Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy NCT04524728 | Istituti Clinici Scientifici Maugeri SpA | — |
| Completed | A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification NCT02435121 | Sanofi | Phase 2 |
| Completed | A Study of SAR428926 in Patients With Advanced Solid Tumors NCT02575781 | Sanofi | Phase 1 |
| Terminated | Evaluation of SAR408701 in Patients With Advanced Solid Tumors NCT02187848 | Sanofi | Phase 1 |
| Unknown | iKnife REIMS Project NCT04067388 | Imperial College London | — |
| Completed | A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients NCT01985191 | Sanofi | Phase 1 |
| Completed | A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma NCT01943838 | Sanofi | Phase 1 |
| Completed | A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients W NCT01930552 | Sanofi | Phase 1 |
| Completed | Effect of SAR302503 on ECG Activity in Patients With Solid Tumors NCT01836705 | Bristol-Myers Squibb | Phase 1 |
| Completed | Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients NCT01657214 | Sanofi | Phase 1 |
| Completed | A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patien NCT01673737 | Sanofi | Phase 1 |
| Completed | Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen NCT01587040 | Sanofi | Phase 1 / Phase 2 |
| Completed | Phase 1 Safety Testing of SAR405838 NCT01636479 | Sanofi | Phase 1 |
| Completed | A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma NCT01596270 | Sanofi | Phase 1 |
| Completed | Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment NCT01527929 | Sanofi | Phase 1 |
| Completed | A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors NCT01455532 | Sanofi | Phase 1 |
| Completed | Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors NCT01392924 | Sanofi | Phase 1 |
| Completed | Evaluation of End of Life Quality of Care NCT03775304 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor NCT01156870 | Sanofi | Phase 1 |
| Completed | A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors NCT01148615 | Sanofi | Phase 1 |
| Completed | Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment NCT01140607 | Sanofi | Phase 1 |
| Completed | A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies NCT00732992 | Pfizer | Phase 1 |